Fractyl Health Says REMAIN-1 Meets Six-Month Co-Primary Endpoint
Fractyl Health said Revita showed a statistically significant reduction in weight regain versus sham (p=0.0023). The company plans a De Novo FDA submission for late Q4 2026 and expects 12-month data in Q1 2027.